CDK Global has successfully renewed its DMS agreement with Sonic Automotive, securing a key partnership following two ...

Genentech’s parent company Roche said the $850m deal lines up with its plan to focus on three therapeutic areas including ...

RHHBY has strengthened its pipeline with an agreement to acquire Regor's portfolio of next-generation CDK inhibitors for the treatment of breast cancer.

In Hybrids amidst financial challenges. Read More CDK Global extends DMS contract with Sonic Automotive amid cyberattack ...

Genentech has acquired Regor Pharmaceuticals’ next-generation CDK inhibitors for breast cancer treatment in a deal worth ...

The news reinforces CDK's reputation in the DMS business and, presumably, will help the company land more extensions and new ...

It hasn’t been the best of years for CDK Global, but it got some good news Monday. Sonic Automotive, one of the nation’s ...

The contract extension with Sonic is a win for market leader CDK, which faced challenges over the summer after two ...

The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...